<code id='297BB36FEC'></code><style id='297BB36FEC'></style>
    • <acronym id='297BB36FEC'></acronym>
      <center id='297BB36FEC'><center id='297BB36FEC'><tfoot id='297BB36FEC'></tfoot></center><abbr id='297BB36FEC'><dir id='297BB36FEC'><tfoot id='297BB36FEC'></tfoot><noframes id='297BB36FEC'>

    • <optgroup id='297BB36FEC'><strike id='297BB36FEC'><sup id='297BB36FEC'></sup></strike><code id='297BB36FEC'></code></optgroup>
        1. <b id='297BB36FEC'><label id='297BB36FEC'><select id='297BB36FEC'><dt id='297BB36FEC'><span id='297BB36FEC'></span></dt></select></label></b><u id='297BB36FEC'></u>
          <i id='297BB36FEC'><strike id='297BB36FEC'><tt id='297BB36FEC'><pre id='297BB36FEC'></pre></tt></strike></i>

          entertainment

          entertainment

          author:explore    Page View:1
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Republican states more likely to report Covid vaccine side effects
          Republican states more likely to report Covid vaccine side effects

          AdobePeopleinRepublican-votingstatesweremorelikelytoreportadverseeventsafterreceivingaCovid-19vaccin

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Artificial intelligence use in health care faces greater scrutiny in 2024

          AdobeIfthepastyearwasprelude,theU.S.governmentin2024ispoisedtore-writetherulessurroundingtheuseofart